R11 Head-to-Head Comparison Reveals Divergent FIH Operational Models
Source type:
obs· Harvested: 2026-05-02 · Original date: 2026-05-02T03:24:00.000Z Metadata:{"project":"lunhsiangyuan","type":"feature","obs_id":64914}
obs/64914 · feature · 2026-05-02T03:24:00.000Z
R11 Head-to-Head Comparison Reveals Divergent FIH Operational Models
Round 11 of the 15-round FIH intelligence report completed a comprehensive head-to-head operational comparison between ADC and bispecific FIH trials. Python script r11_h2h.py queried FIH Scout database for status distribution, failure rates, multi-site patterns, site overlap, and sponsor concentration across 107 ADC FIH and 127 bispecific FIH trials. Analysis revealed fundamentally different operational models: ADC follows a “large army” approach (平均 17 sites, 222 patients, 48% large multi-site trials) driven by CMC maturity and predictable payload toxicity, while bispecific follows an “elite strike force” approach (平均 12 sites, 131 patients, 35% single-site trials) driven by CRS safety management requiring intensive ICU support. The 2x failure rate differential (ADC 3.7% vs bispecific 7.9%) reflects platform leverage for ADC where same payload/linker can be reused across targets versus de novo risk for each bispecific target pair. Only 170 sites have conducted both modality types, making them the most valuable resource for sponsors planning dual-modality pipelines. Report section includes comparative table, ASCII visualization contrasting “大部隊行軍” versus “精銳突擊隊”, site overlap breakdown (707 ADC-only, 475 bispecific-only, 170 dual), and four strategic judgments including the critical insight that the two modalities should not share the same site recommendation list.
Concepts: [“how-it-works”,“what-changed”,“pattern”,“problem-solution”]
Facts: [“ADC FIH trials average 17 sites and 222 patients with 3.7% failure rate, bispecific FIH trials average 12 sites and 131 patients with 7.9% failure rate”,“Bispecific FIH trials show 35% single-site prevalence versus 18% for ADC, reflecting CRS safety concerns requiring ICU-ready sites”,“Only 170 sites (12.6% of combined pool) conduct both ADC and bispecific FIH trials, representing the scarcest dual-modality resource”,“ADC failure rate (3.7%) is half of bispecific (7.9%), but bispecific completion rate (11.8%) is 3x higher than ADC (3.7%)”,“R11 section added to output/adc-bispecific-landscape.md with comprehensive comparison table across 13 dimensions and ASCII operational model visualization”]
[← 回 Alfred Brain Hub]